Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial

T Seto, S Ushijima, H Yamamoto, K Ito, J Araki, Y Inoue, H Semba, Y Ichinose, Thoracic Oncology Group, T Seto, S Ushijima, H Yamamoto, K Ito, J Araki, Y Inoue, H Semba, Y Ichinose, Thoracic Oncology Group

Abstract

To assess the effect and toxicity of hypotonic cisplatin treatment (HPT) consisting of the intrapleural administration of cisplatin in distilled water for malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). Non-small-cell lung cancer patients with cytologically proven and previously untreated malignant pleural effusion were enrolled into this study. Firstly, the lung was fully re-expanded by a tube thoracostomy, and then 25 mg cisplatin in 500 ml of distilled water was instilled through a chest tube and then the tube was clamped. After 1 h, the tube was declamped and allowed to drain. The chest tube was removed when the pleural effusion volume decreased to 200 ml or less per day. A complete response (CR) was considered to occur when the pleural effusion disappeared. A partial response (PR) was determined to occur when the volume of pleural effusion remained under (1/4) of hemithorax. The response at 4 weeks was evaluated by an extramural review. Out of 84 patients enrolled from February 1998 to August 2002, 80 patients were eligible and analysed in the present study. The toxicity of HPT was acceptable. Neither a haematological toxicity of any grade nor grade 4 nonhaematological toxicity was observed. Grade 3 nonhaematological toxicities were observed, including nausea (4%), vomiting (3%), pyothorax (1%) and dyspnoea (1%). The median time of drainage from HTP was 4 days. Twenty-seven (34%) and 39 (49%) patients achieved CR and PR, respectively, for an overall response rate of 83% (95% confidence interval, 74-91%). The median duration of the response was 206 days. The median survival time of all patients was 239 days. Hypotonic cisplatin treatment for malignant pleural effusion of NSCLC is therefore considered to be feasible and effective. A phase III study of HPT is thus warranted.

Figures

Figure 1
Figure 1
Overall survival and progression-free survival. Each tick mark and bar represents a patient who is alive and the 95% confidence interval of the survival rate, respectively.

References

    1. Chernow B, Sahn SA (1977) Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 63: 695–702
    1. Desai SD, Figueredo A (1979) Intracavitary doxorubicin in malignant effusions. Lancet 1: 872 (letter)
    1. Hartman DL, Gaither JM, Kesler KA, Mylet DM, Brown JW, Mathur PN (1993) Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 105: 743–747 (discussion 747–748)
    1. Hausheer FH, Yarbro JW (1985) Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12: 54–75
    1. Holoye PY, Jeffries DG, Dhingra HM, Holmes FA, Raber M, Engineer MS, Newman RA (1990) Intrapleural etoposide for malignant effusion. Cancer Chemother Pharmacol 26: 147–150
    1. Ichinose Y, Hara N, Ohta M, Asoh H, Yano T, Maeda K, Yagawa K (1993) Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results. J Thorac Cardiovasc Surg 105: 1041–1046
    1. Ichinose Y, Tsuchiya R, Koike T, Yasumitsu T, Nakamura K, Tada H, Yoshimura H, Mitsudomi T, Nakagawa K, Yokoi K, Kato H (2002) A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg 123: 695–699
    1. Ichinose Y, Yano T, Asoh H, Yokoyama H, Fukuyama Y, Miyagi J, Kuninaka S, Terazaki Y (1997) Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. J Surg Oncol 66: 196–200
    1. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ, Lee LN (1992) Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69: 674–679
    1. Moffett MJ, Ruckdeschel JC (1992) Bleomycin and tetracycline in malignant pleural effusions: a review. Semin Oncol 19: 59–62 (discussion 62–53)
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
    1. Putnam Jr JB, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, Lee RB, Payne DK, Graeber G, Kovitz KL (1999) A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 86: 1992–1999
    1. Rosenberg B (1978) Platinum complex–DNA interactions and anticancer activity. Biochimie 60: 859–867
    1. Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Mandelbaum I, Koeller J, Weiss GR, Losada M, Keller JH (1991) Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest 100: 1528–1535
    1. Rusch VW, Figlin R, Godwin D, Piantadosi S (1991) Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9: 313–319
    1. Saka H, Shimokata K, Watanabe A, Saito H, Minami H, Sakai S (1994) Randomized comparision of OK-432 and bleomycin in intrapleural therapy for malignant pleural effusion. Proc Am Soc Clin Oncol 13: 450
    1. Shan SA (1987) Malignant pleural effusion. Semin Respir Med 9: 43–53
    1. Sherman SE, Lippard SJ (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87: 1153–1181
    1. Suhrland LG, Weisberger AS (1965) Intracavity 5-fluorouracil in malignant effusion. Arch Intern Med 116: 431–433
    1. Tohda Y, Iwanaga T, Takada M, Yana T, Kawahara M, Negoro S, Okishio K, Kudoh S, Fukuoka M, Furuse K (1999) Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 45: 197–204
    1. Ushijima S, Nakamoto K, Ueda K (1997) Experiment of hypotonic cisplatin treatment for malignant pleural effusion. Kyoubu Shikkan Gakkai Zasshi 35(Suppl): 310 (Japanese)
    1. Walker-Renard PB, Vaughan LM, Sahn SA (1994) Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120: 56–64

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다